American Society of Hirudotherapy

Treatment of acute ischemic stroke: recent progress.

Research article published in Internal medicine (Tokyo, Japan) (2002)

Last Updated: June 18, 2026Reviewed by: ASH Editorial Board
Research article — evidence reviewArticle reference
Evidence: Narrative reviewClinical TrialsTanahashi et al. · Internal medicine (Tokyo, Japan), 2002

Abstract

Intravenous thrombolysis with tissue plasminogen activator is currently the most effective treatment of acute ischemic stroke if administerd within 3 hours after symptom onset. Intraarterial thrombolysis by prourokinase is the another choise if the middle cerebral artery is occluded and within less than 6 hours after onset. Although heparin especially a moderate dose is not proved to be effective, a randomized, placebo-controlled trial to determine the safety and efficacy of argatroban (a selective thrombin inhibitor) in patients with acute ischemic stroke was started in USA. Aspirin provides some benefit to patients with acute stroke. However, its effect is not fully satisfactory. Although reports of numerous trials for neuroprotective drugs have been disappointing, edaravone (free radical scavenger) was approved for the treatment of acute ischemic stroke in Japan. In the future, thrombolytic and neuroprotective drugs will be used in combination.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview
Indexed MeSH termsAnticoagulantsClinical Trials as TopicFibrinolytic AgentsHumansNeuroprotective AgentsStrokeThrombolytic Therapy

Summary

Treatment of acute ischemic stroke: recent progress.

Why This Matters for Hirudotherapy

This review summarizes recent progress in the treatment of acute ischemic stroke, discussing intravenous tissue plasminogen activator within 3 hours of onset, intra-arterial prourokinase for middle cerebral artery occlusion, aspirin, the free radical scavenger edaravone approved in Japan, and a trial of argatroban that was started in the USA. The article mentions argatroban as a selective thrombin inhibitor being investigated for acute stroke, but does not discuss hirudin, leeches, or any leech-derived compound. Argatroban is a synthetic agent with no connection to the leech secretome described in this abstract. This article has no defensible relevance to hirudotherapy or ASH's domain.

Citation

Treatment of acute ischemic stroke: recent progress.

Tanahashi et al. · Internal medicine (Tokyo, Japan), 2002

DOI

Added to ASH library: May 28, 2026 · Site last updated: June 18, 2026

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.